Clene Inc. to Present Corporate Update at Emerging Growth Conference

Clene Inc., a biopharmaceutical company developing innovative therapies for neurodegenerative diseases, will host a virtual corporate update at the Emerging Growth Conference on April 17, 2025. The presentation, scheduled for 12:00 p.m. EDT, will feature a live Q&A session and be accessible via webcast on the company's website and conference portal.

The update represents a significant opportunity for investors and healthcare professionals to gain insights into Clene's strategic developments and progress in treating complex neurological conditions. The company is primarily focused on advancing CNM-Au8, an investigational therapy designed to improve mitochondrial health and neuronal function for patients with challenging disorders such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis.

CNM-Au8 is positioned as a potentially groundbreaking treatment that targets mitochondrial function and the NAD pathway while simultaneously reducing oxidative stress. This unique approach could offer meaningful therapeutic possibilities for patients with neurodegenerative diseases, where current treatment options remain limited.

The conference presentation will likely provide critical updates on ongoing clinical programs and potential milestones for the company's lead therapeutic candidate. For the medical and scientific community, such updates are crucial in understanding emerging treatment strategies for complex neurological conditions.

By continuing to advance its research and development efforts, Clene demonstrates commitment to addressing significant unmet medical needs in neurodegenerative disease treatment. The virtual corporate update offers a transparent platform for sharing the company's latest scientific progress and potential therapeutic innovations.